



**18 May 2021**  
**ASX ANNOUNCEMENT**

**Perth Australia, 18 May 2021:** Neuroscientific Biopharmaceuticals (ASX : NSB) wishes to advise that it has today accepted the resignation of Non-Executive Chairman, Mr Brian Leedman, effective 18 May 2021.

Speaking on behalf of the Company, Managing Director Matthew Liddelow said "Brian played a key role in the company's progress to date and his broad biotech experience and immense network and capital market expertise were instrumental to NSB's progress since our IPO in 2018. He leaves the Company in great shape, with the business poised to start Phase I clinical studies this year. As a Board we are extremely grateful for his contribution and wish him all the best in his new recently announced role with another business".

Until such time as a replacement Chairman is appointed, Dr Anton Uvarov will function as interim Chairman, with effect from today.

**About Neuroscientific Biopharmaceuticals Limited**

NeuroScientific Biopharmaceuticals (ASX:NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit [www.neuroscientific.com](http://www.neuroscientific.com)

**END**

***Announcement authorised by the Board of Directors of NeuroScientific Biopharmaceuticals***

**Contacts**

Matthew Liddelow  
CEO and Managing Director  
[ml@neuroscientific.com](mailto:ml@neuroscientific.com)  
+61 8 6382 1805